|
1
|
Jemal A, Murray T, Ward E, et al: Cancer
statistics, 2005. CA Cancer J Clin. 55:10–30. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Parkin DM, Bray FL and Devesa SS: Cancer
burden in the year 2000. The global picture. Eur J Cancer. 37:4–66.
2001. View Article : Google Scholar
|
|
3
|
Parkin DM: International variation.
Oncogene. 23:6329–6340. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glover DM, Hagan IM and Tavares AA:
Polo-like kinases: a team that plays throughout mitosis. Gene Dev.
12:3777–3787. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Barr FA, Sillje HH and Nigg EA: Polo-like
kinases and the orchestration of cell division. Nat Rev Mol Cell
Biol. 5:429–440. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Andrysik Z, Bernstein WZ, Deng L, et al:
The novel mouse polo-like kinase 5 responds to DNA damage and
localizes in the nucleolus. Nucleic Acids Res. 38:2931–2943. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Archambault V and Glover DM: Polo-like
kinases: conservation and divergence in their functions and
regulation. Nat Rev Mol Cell Biol. 10:265–275. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ma S, Charron J, Erikson RL, et al: Role
of plk2 (Snk) in mouse development and cell proliferation. Mol Cell
Biol. 23:6936–6943. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kauselmann G, Weiler M, Wulff P, et al:
The polo-like protein kinases Fnk and Snk associate with a Ca(2+)-
and integrin-binding protein and are regulated dynamically with
synaptic plasticity. EMBO J. 18:5528–5539. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Syed N, Smith P, Sullivan A, et al:
Transcriptional silencing of polo-like kinase 2 (SNK/PLK2) is a
frequent event in B-cell malignancies. Blood. 107:250–256. 2006.
View Article : Google Scholar
|
|
11
|
Smith P, Syed N and Crook T: Epigenetic
inactivation implies a tumor suppressor function in hematologic
malignancies for Polo-like kinase 2 but not Polo-like kinase 3.
Cell Cycle. 5:1262–1264. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pellegrino R, Calvisi DF, Ladu S, et al:
Oncogenic and tumor suppressive roles of polo-like kinases in human
hepatocellular carcinoma. Hepatology. 51:857–868. 2010.PubMed/NCBI
|
|
13
|
Kothari V, Wei I, Shankar S, et al:
Outlier kinase expression by RNA sequencing as targets for
precision therapy. Cancer Discov. 3:280–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Radonića A, Thulkea S, Mackayb IM, et al:
Guideline to reference gene selection for quantitative real-time
PCR. Biochem Biophys Res Common. 313:856–862. 2004. View Article : Google Scholar
|
|
15
|
Li F, Jo M, Curry TE Jr and Liu J:
Hormonal induction of polo-like kinases (Plks) and impact of Plk2
on cell cycle progression in the rat ovary. PLoS One. 7:e41–e44.
2012.
|
|
16
|
Warnke S, Kemmler S, Hames RS, et al:
Polo-like kinase-2 is required for centriole duplication in
mammalian cells. Curr Biol. 14:1200–1207. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simmons DL, Neel BG, Stevens R, et al:
Identification of an early-growth-response gene encoding a novel
putative protein kinase. Mol Cell Biol. 12:4164–4169.
1992.PubMed/NCBI
|
|
18
|
Burns TF, Fei P, Scata KA, et al:
Silencing of the novel p53 target gene Snk/Plk2 leads to mitotic
catastrophe in paclitaxel (taxol)-exposed cells. Mol Cell Biol.
23:5556–5571. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Strebhardt K: Multifaceted polo-like
kinases: drug targets and antitargets for cancer therapy. Nat Rev
Drug Discov. 9:643–660. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li Z, Lu J, Sun M, et al: Distinct
microRNA expression profiles in acute myeloid leukemia with common
translocations. Proc Natl Acad Sci USA. 105:15535–15540. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miko E, Margitai Z, Czimmerer Z, et al:
miR-126 inhibits proliferation of small cell lung cancer cells by
targeting SLC7A5. FEBS Lett. 585:1191–1196. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lagos-Quintana M, Rauhut R, Yalcin A, et
al: Identification of tissue-specific microRNAs from mouse. Curr
Biol. 12:735–739. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang S, Aurora AB, Johnson BA, et al: The
endothelial-specific microRNA miR-126 governs vascular integrity
and angiogenesis. Dev Cell. 15:261–271. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fish JE, Santoro MM, Morton SU, et al:
miR-126 regulates angiogenic signaling and vascular integrity. Dev
Cell. 15:272–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Feng R, Chen X, Yu Y, et al: miR-126
functions as a tumour suppressor in human gastric cancer. Cancer
Lett. 298:50–63. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu LY, Wang W, Zhao LY, et al: miR-126
inhibits growth of SGC-7901 cells by synergistically targeting the
oncogenes PI3KR2 and Crk, and the tumor suppressor PLK2. Int J
Oncol. 45:1257–1265. 2014.PubMed/NCBI
|
